PMID- 20389302
OWN - NLM
STAT- MEDLINE
DCOM- 20100528
LR  - 20211020
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 102
IP  - 9
DP  - 2010 Apr 27
TI  - Self-reported health-related quality of life is an independent predictor of 
      chemotherapy treatment benefit and toxicity in women with advanced breast cancer.
PG  - 1341-7
LID - 10.1038/sj.bjc.6605649 [doi]
AB  - BACKGROUND: Baseline health-related quality of life (QL) is associated with 
      survival in advanced breast cancer. We sought to identify patients who were less 
      likely to respond to chemotherapy and at greater risk of toxicity on the basis of 
      their QL. METHODS: We used data from three advanced breast cancer trials in which 
      patients (n=378) were treated with cyclophosphamide, methotrexate and 
      5-fluouracil. Patients self-rated their QL using LASA scales for physical 
      well-being (PWB), mood, pain, nausea/vomiting, appetite and overall QL. 
      Multivariable regression models were constructed to compare overall survival 
      (OS), objective tumour response (OTR), adverse events (AEs) and weight loss 
      according to grouped QL scores. RESULTS: Physical well-being, mood, appetite and 
      overall QL were significant univariable predictors of OS. Physical well-being and 
      appetite remained significant after adjustment for baseline biomedical factors. 
      Poor PWB was associated with lower OTR (odds ratio (OR)=0.21, 95% confidence 
      interval (CI) 0.09-0.51), higher risk of non-haematological AEs (OR=3.26, 95% CI 
      1.49-7.15) and greater risk of weight loss (OR 2.37, 95% CI 1.12-5.01) compared 
      with good PWB. CONCLUSION: In women with advanced breast cancer, PWB and appetite 
      are predictors of chemotherapy response and toxicity as well as survival. Quality 
      of life should be a routine clinical assessment to guide patient selection for 
      chemotherapy and for stratification of patients in clinical trials.
FAU - Lee, C K
AU  - Lee CK
AD  - NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW, 
      Australia. chee.lee@ctc.usyd.edu.au
FAU - Stockler, M R
AU  - Stockler MR
FAU - Coates, A S
AU  - Coates AS
FAU - Gebski, V
AU  - Gebski V
FAU - Lord, S J
AU  - Lord SJ
FAU - Simes, R J
AU  - Simes RJ
CN  - Australian New Zealand Breast Cancer Trials Group
LA  - eng
PT  - Journal Article
DEP - 20100413
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
SB  - IM
MH  - Affect
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Appetite
MH  - Breast Neoplasms/*drug therapy/mortality/*pathology/psychology
MH  - Disease-Free Survival
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Middle Aged
MH  - Nausea/epidemiology
MH  - Neoplasm Metastasis/drug therapy
MH  - Postmenopause
MH  - *Quality of Life
MH  - Receptors, Estrogen/analysis
MH  - Receptors, Progesterone/analysis
MH  - Regression Analysis
MH  - Self Concept
MH  - Survival Analysis
MH  - Survivors
MH  - Vomiting/epidemiology
MH  - Weight Loss
PMC - PMC2865758
EDAT- 2010/04/15 06:00
MHDA- 2010/05/29 06:00
PMCR- 2011/04/27
CRDT- 2010/04/15 06:00
PHST- 2010/04/15 06:00 [entrez]
PHST- 2010/04/15 06:00 [pubmed]
PHST- 2010/05/29 06:00 [medline]
PHST- 2011/04/27 00:00 [pmc-release]
AID - 6605649 [pii]
AID - 10.1038/sj.bjc.6605649 [doi]
PST - ppublish
SO  - Br J Cancer. 2010 Apr 27;102(9):1341-7. doi: 10.1038/sj.bjc.6605649. Epub 2010 
      Apr 13.